| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 35.87 | 4.9% |
| Total Income | 36.15 | 7.5% |
| Expenditure | 24.03 | 4.5% |
| PBT | 12.12 | 24.7% |
| Net Profit | 9.06 | 24.5% |
| OPM | 38.81% | 3.69pp |
| NPM | 25.07% | 5.63pp |
| EPS | 0.83 | 24.6% |
Gujarat Themis Biosyn Ltd Reports Strong FY2024-25 Performance, Announces AGM and Capital Expenditure Plan
19 Aug 2025 · 19 Aug 2025, 10:02 pm
Summary
Gujarat Themis Biosyn Ltd has reported strong financial performance for the financial year ended 31st March, 2025. The company's revenue stood at Rs. 150.8 crores, while EBITDA and PAT were at Rs. 68.8 crores and Rs. 48.8 crores respectively. The company is executing a capital expenditure plan which includes the commissioning of a new R&D facility, a dedicated API block, and additional fermentation capacity. The AGM is scheduled for 12th September, 2025.
Key Highlights
- 1
Revenue of Rs. 150.8 crores for FY2024-25
- 2
EBITDA of Rs. 68.8 crores for FY2024-25
- 3
PAT of Rs. 48.8 crores for FY2024-25
- 4
Commissioning of Phase 1 of new R&D facility
- 5
Completion of dedicated API block
- 6
Creation of additional fermentation capacity
- 7
AGM scheduled for 12th September, 2025
Management Comments
Dr. Dinesh S. Patel
Message from Chairman: Dear Valued Stakeholders, It gives me great pleasure to address you all at the onset of the new fiscal year. I would like to start by conveying my gratitude to all our stakeholders, partners and employees for their continuous support in our journey.
Informational and educational content only. Not investment advice.